Clinical Trial Update: Trial Evaluating the Efficacy of Pimavanserin, a Selective Serotonin 5-HydroxyTryptamine-2A (5HT2A) Inverse Agonist, to Treat Impulse Control Disorders in Parkinson's Disease.

View source ↗

Summary

This clinical trial update describes a study evaluating pimavanserin for impulse control disorders in Parkinson's disease, with the study currently not yet recr…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Nuplazid (Pimavanserin)

Snippet

Sponsor: University Hospital, Strasbourg, France | Conditions: Parkinson Disease | Status: NOT_YET_RECRUITING